Welcome to DrugBank 4.0! If you prefer, you can still go back to version 3.0.
Identification
NameNedocromil
Accession NumberDB00716  (APRD01137)
Typesmall molecule
Groupsapproved
Description

A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
NedocromilNot AvailableINN, BAN, USAN
NedocromiloSpanishNot Available
NedocromilumLatinNot Available
SaltsNot Available
Brand names
NameCompany
AlocrilNot Available
TiladeNot Available
Brand mixturesNot Available
Categories
CAS number69049-73-6
WeightAverage: 371.3408
Monoisotopic: 371.100501903
Chemical FormulaC19H17NO7
InChI KeyInChIKey=RQTOOFIXOKYGAN-UHFFFAOYSA-N
InChI
InChI=1S/C19H17NO7/c1-3-5-9-16-10(13(21)7-12(18(23)24)20(16)4-2)6-11-14(22)8-15(19(25)26)27-17(9)11/h6-8H,3-5H2,1-2H3,(H,23,24)(H,25,26)
IUPAC Name
9-ethyl-4,6-dioxo-10-propyl-4H,6H,9H-chromeno[7,6-b]pyridine-2,8-dicarboxylic acid
SMILES
CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O
Mass SpecNot Available
Taxonomy
KingdomOrganic Compounds
SuperclassHeterocyclic Compounds
ClassBenzopyrans
SubclassChromenopyridines
Direct parentChromenopyridines
Alternative parentsQuinoline Carboxylic Acids; Chromones; Hydroquinolones; Hydroquinolines; Alpha Amino Acids and Derivatives; Pyridinecarboxylic Acids; Pyranones and Derivatives; Dicarboxylic Acids and Derivatives; Benzene and Substituted Derivatives; Polyols; Carboxylic Acids; Enolates; Polyamines
Substituentsdihydroquinolone; chromone; alpha-amino acid or derivative; dihydroquinoline; quinoline; pyridine carboxylic acid or derivative; pyridine carboxylic acid; pyranone; pyran; pyridine; benzene; dicarboxylic acid derivative; polyol; carboxylic acid derivative; polyamine; enolate; carboxylic acid; amine; organonitrogen compound
Classification descriptionThis compound belongs to the chromenopyridines. These are aromatic heterocyclic compounds structurally characterized by a pyridine ring fused to a chromene moiety.
Pharmacology
IndicationFor the treatment of mild to moderate asthma
PharmacodynamicsNedocromil is a anti-inflammatory agent and can be administered directly to the bronchial mucosa. It has significant inhibitory effect on allergen-induced early and late asthmatic reactions and on bronchial hyperresponsiveness.
Mechanism of actionNedocromil has been shown to inhibit the in vitro activation of, and mediator release from, a variety of inflammatory cell types associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets. Nedocromil inhibits activation and release of inflammatory mediators such as histamine, prostaglandin D2 and leukotrienes c4 from different types of cells in the lumen and mucosa of the bronchial tree. These mediators are derived from arachidonic acid metabolism through the lipoxygenase and cyclo-oxygenase pathways. The mechanism of action of nedocromil may be due partly to inhibition of axon reflexes and release of sensory neuropeptides, such as substance P, neurokinin A, and calcitonin-geneñrelated peptides. The result is inhibition of bradykinin-induced bronchoconstriction. Nedocromil does not posess any bronchodilator, antihistamine, or corticosteroid activity.
AbsorptionLow
Volume of distributionNot Available
Protein bindingapproximately 89% protein bound in human plasma over a concentration range of 0.5 to 50 µg/mL
Metabolism

Nedocromil is not metabolized after IV administration and is excreted unchanged.

Route of eliminationIt is not metabolized and is eliminated primarily unchanged in urine (70%) and feces (30%).
Half life~3.3 hours
ClearanceNot Available
ToxicitySide effects include headache, nasal congestion, ocular burning, irritation and stinging, unpleasant taste, cough, difficulty breathing, noisy breathing, shortness of breath, tightness in chest, wheezing, conjunctivitis, blurred vision, change in color vision, difficulty seeing at night, increased sensitivity of eyes to sunlight.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.917
Blood Brain Barrier - 0.7048
Caco-2 permeable - 0.5125
P-glycoprotein substrate Substrate 0.5954
P-glycoprotein inhibitor I Non-inhibitor 0.8426
P-glycoprotein inhibitor II Non-inhibitor 0.5435
Renal organic cation transporter Non-inhibitor 0.8157
CYP450 2C9 substrate Non-substrate 0.8194
CYP450 2D6 substrate Non-substrate 0.8091
CYP450 3A4 substrate Non-substrate 0.5338
CYP450 1A2 substrate Inhibitor 0.7062
CYP450 2C9 substrate Non-inhibitor 0.8555
CYP450 2D6 substrate Non-inhibitor 0.9076
CYP450 2C19 substrate Non-inhibitor 0.6715
CYP450 3A4 substrate Non-inhibitor 0.8646
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8278
Ames test Non AMES toxic 0.6198
Carcinogenicity Non-carcinogens 0.9488
Biodegradation Not ready biodegradable 0.9798
Rat acute toxicity 2.6400 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9113
hERG inhibition (predictor II) Non-inhibitor 0.8385
Pharmacoeconomics
Manufacturers
  • King pharmaceuticals inc
  • Allergan inc
  • Sanofi aventis us llc
Packagers
Dosage forms
FormRouteStrength
LiquidOphthalmic
Prices
Unit descriptionCostUnit
Alocril 2% Solution 5ml Bottle100.57USDbottle
Alocril 2% eye drops19.34USDml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United StatesRE386281992-08-222012-08-22
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point299 dec °CPhysProp
water solubility145 mg/LNot Available
logP2.22SANGSTER (1994)
Predicted Properties
PropertyValueSource
water solubility4.59e-02 g/lALOGPS
logP2.18ALOGPS
logP2.5ChemAxon
logS-3.9ALOGPS
pKa (strongest acidic)2.28ChemAxon
pKa (strongest basic)-4.2ChemAxon
physiological charge-2ChemAxon
hydrogen acceptor count8ChemAxon
hydrogen donor count2ChemAxon
polar surface area121.21ChemAxon
rotatable bond count5ChemAxon
refractivity98.09ChemAxon
polarizability36.95ChemAxon
number of rings3ChemAxon
bioavailability1ChemAxon
rule of fiveYesChemAxon
Ghose filterYesChemAxon
Veber's ruleNoChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraNot Available
References
Synthesis Reference

Andrew R. Clark, “Nedocromil sodium compositions and methods for their preparation.” U.S. Patent US4935244, issued July, 1988.

US4935244
General ReferenceNot Available
External Links
ResourceLink
KEGG DrugD05129
KEGG CompoundC07255
PubChem Compound50294
PubChem Substance46507587
ChemSpider45608
ChEBI7492
ChEMBLCHEMBL746
PharmGKBPA450601
Drug Product Database2241407
RxListhttp://www.rxlist.com/cgi/generic3/nedocr.htm
Drugs.comhttp://www.drugs.com/cdi/nedocromil-drops.html
PDRhealthhttp://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/til1444.shtml
WikipediaNedocromil
ATC CodesR01AC07R03BC03S01GX04
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelshow(362 KB)
MSDSNot Available
Interactions
Drug InteractionsSearched, but no interactions found.
Food InteractionsNot Available

1. Cysteinyl leukotriene receptor 1

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: suppressor

Components

Name UniProt ID Details
Cysteinyl leukotriene receptor 1 Q9Y271 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Monteseirin J, Chacon P, Vega A, Sanchez-Monteseirin H, Asturias JA, Martinez A, Guardia P, Perez-Cano R, Conde J: L-selectin expression on neutrophils from allergic patients. Clin Exp Allergy. 2005 Sep;35(9):1204-13. Pubmed
  4. Yazid S, Leoni G, Getting SJ, Cooper D, Solito E, Perretti M, Flower RJ: Antiallergic cromones inhibit neutrophil recruitment onto vascular endothelium via annexin-A1 mobilization. Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1718-24. Epub 2010 Jun 17. Pubmed
  5. Radeau T, Godard P, Chavis C, Michel FB, Descomps B, Damon M: Effect of nedocromil sodium on sulfidopeptide leukotrienes-stimulated human alveolar macrophages in asthma. Pulm Pharmacol. 1993 Mar;6(1):27-31. Pubmed

2. Cysteinyl leukotriene receptor 2

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Cysteinyl leukotriene receptor 2 Q9NS75 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Monteseirin J, Chacon P, Vega A, Sanchez-Monteseirin H, Asturias JA, Martinez A, Guardia P, Perez-Cano R, Conde J: L-selectin expression on neutrophils from allergic patients. Clin Exp Allergy. 2005 Sep;35(9):1204-13. Pubmed
  4. Yazid S, Leoni G, Getting SJ, Cooper D, Solito E, Perretti M, Flower RJ: Antiallergic cromones inhibit neutrophil recruitment onto vascular endothelium via annexin-A1 mobilization. Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1718-24. Epub 2010 Jun 17. Pubmed

3. fMet-Leu-Phe receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
fMet-Leu-Phe receptor P21462 Details

References:

  1. Peroni DG, Melotti P, Piacentini GL, Bonizzato C, Boner AL: Effects of nedocromil sodium on the binding of N-formyl-methionyl-leucyl-phenylalanine in human neutrophils. Agents Actions. 1992 Jul;36(3-4):212-4. Pubmed
  2. Carolan EJ, Casale TB: Effects of nedocromil sodium and WEB 2086 on chemoattractant-stimulated neutrophil migration through cellular and noncellular barriers. Ann Allergy. 1992 Oct;69(4):323-8. Pubmed
  3. Warringa RA, Mengelers HJ, Maikoe T, Bruijnzeel PL, Koenderman L: Inhibition of cytokine-primed eosinophil chemotaxis by nedocromil sodium. J Allergy Clin Immunol. 1993 Mar;91(3):802-9. Pubmed

4. Prostaglandin D2 receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: unknown

Components

Name UniProt ID Details
Prostaglandin D2 receptor Q13258 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Lane SJ, Lee TH: Mast cell effector mechanisms. J Allergy Clin Immunol. 1996 Nov;98(5 Pt 2):S67-71; discussion S71-2. Pubmed
  4. Ahluwalia P, Anderson DF, Wilson SJ, McGill JI, Church MK: Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms. J Allergy Clin Immunol. 2001 Sep;108(3):449-54. Pubmed

5. Heat shock protein HSP 90-alpha

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Heat shock protein HSP 90-alpha P07900 Details

References:

  1. Okada M, Itoh H, Hatakeyama T, Tokumitsu H, Kobayashi R: Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41. Pubmed
  2. Nishikawa M, Takemoto S, Takakura Y: Heat shock protein derivatives for delivery of antigens to antigen presenting cells. Int J Pharm. 2008 Apr 16;354(1-2):23-7. Epub 2007 Sep 29. Pubmed

Comments
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11